Reduction in neutrophil count during hepatitis c treatment: Drug toxicity or predictor of good response?

Digestive Diseases and Sciences

Volumn 55, Issue 7, 2010, Pages 2058-2062

  Alvarez Uria, Gerardo ^a,b   Day, Jeremy N ^a,c   Nasir, Anisa J ^a   Russell, Susan K ^a   Vilar, F Javier ^a  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

Hepatitis C; Neutropenia; Peginterferon; Treatment outcome

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; NEUTROPHILS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RISK ASSESSMENT; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954394388     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0969-z     Document Type: Article

References (17)

1. DB Strader T Wright DL Thomas LB Seeff 2004 Diagnosis, management, and treatment of hepatitis C Hepatology 39 1147 1171 10.1002/hep.20119 15057920 (Pubitemid 38428955)
2. GC Sen 2001 Viruses and interferons Annu Rev Microbiol 55 255 281 10.1146/annurev.micro.55.1.255 1:CAS:528:DC%2BD3MXnslKjt7g%3D 11544356 (Pubitemid 32978106)
3. JJ Feld JH Hoofnagle 2005 Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 967 972 10.1038/nature04082 1:CAS:528:DC%2BD2MXotFent7c%3D 16107837 (Pubitemid 41191673)
4. M Schmid A Kreil W Jessner M Homoncik C Datz A Gangl P Ferenci M Peck-Radosavljevic 2005 Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens Gut 54 1014 1020 10.1136/gut.2004.057893 1:CAS:528:DC%2BD2MXmsFKqtrk%3D 15951552 (Pubitemid 40873919)
5. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr D Haussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D 12324553
6. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 10.1016/S0140-6736(01)06102- 5 1:CAS:528:DC%2BD3MXntF2qtb8%3D 11583749 (Pubitemid 32913521)
7. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer Jr D Bernstein M Rizzetto S Zeuzem PJ Pockros A Lin AM Ackrill 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
8. J Crawford DC Dale GH Lyman 2004 Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228 237 10.1002/cncr.11882 14716755 (Pubitemid 38063629)
9. JL Dienstag JG McHutchison 2006 American gastroenterological association technical review on the management of hepatitis C Gastroenterology 130 231 264 10.1053/j.gastro.2005.11.010 16401486 quiz 214-237 (Pubitemid 43049856)
10. A Soza JE Everhart MG Ghany E Doo T Heller K Promrat Y Park TJ Liang JH Hoofnagle 2002 Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36 1273 1279 10.1053/jhep.2002. 36502 1:CAS:528:DC%2BD38XovFaktrk%3D 12395340 (Pubitemid 35253446)
11. IM Jacobson RS Brown Jr B Freilich N Afdhal PY Kwo J Santoro S Becker AE Wakil D Pound E Godofsky R Strauss D Bernstein S Flamm MP Pauly P Mukhopadhyay LH Griffel CA Brass 2007 Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 971 981 10.1002/hep.21932 1:CAS:528:DC%2BD2sXht1aksrzE 17894303 (Pubitemid 350144761)
12. ML Shiffman MG Ghany TR Morgan EC Wright GT Everson KL Lindsay AS Lok HL Bonkovsky AM Di Bisceglie WM Lee JL Dienstag DR Gretch 2007 Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 103 112 10.1053/j.gastro.2006.11.011 1:CAS:528:DC%2BD2sXit1aqsLs%3D 17241864 (Pubitemid 46127673)
13. J Koirala SD Gandotra S Rao G Sangwan A Mushtaq TH Htwe A Adamski D Blessman NM Khardori 2007 Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy J Viral Hepat 14 782 787 10.1111/j.1365-2893.2007.00870.x 1:STN:280:DC%2BD2sngsFamsg%3D%3D 17927614 (Pubitemid 47561582)
14. ZM Younossi FH Nader C Bai R Sjogren JP Ong R Collantes M Sjogren D Farmer L Ramsey K Terra H Gujral C Gurung M Srishord Y Fang 2008 A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment J Viral Hepat 15 370 378 10.1111/j.1365-2893.2007.00956.x 1:STN:280:DC%2BD1c3itFSqtw%3D%3D 18194172 (Pubitemid 351473630)
15. KL Lindsay C Morishima EC Wright JL Dienstag ML Shiffman GT Everson AS Lok HL Bonkovsky WM Lee TR Morgan MG Ghany 2008 Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C Clin Gastroenterol Hepatol 6 234 241 10.1016/j.cgh.2007.11.020 1:CAS:528:DC%2BD1cXislCqt7s%3D 18237873 (Pubitemid 351181291)
16. MW Taylor T Tsukahara L Brodsky J Schaley C Sanda MJ Stephens JN McClintick HJ Edenberg L Li JE Tavis C Howell SH Belle 2007 Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy J Virol 81 3391 3401 10.1128/JVI.02640-06 1:CAS:528:DC%2BD2sXjslWqs74%3D 17267482 (Pubitemid 46456648)
17. L Chen I Borozan J Feld J Sun LL Tannis C Coltescu J Heathcote AM Edwards ID McGilvray 2005 Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 1437 1444 10.1053/j.gastro.2005.01.059 1:CAS:528: DC%2BD2MXlt1CisL0%3D 15887125 (Pubitemid 40712193)